MX2012014982A - Formulacion oral de inhibidores de quinasa. - Google Patents

Formulacion oral de inhibidores de quinasa.

Info

Publication number
MX2012014982A
MX2012014982A MX2012014982A MX2012014982A MX2012014982A MX 2012014982 A MX2012014982 A MX 2012014982A MX 2012014982 A MX2012014982 A MX 2012014982A MX 2012014982 A MX2012014982 A MX 2012014982A MX 2012014982 A MX2012014982 A MX 2012014982A
Authority
MX
Mexico
Prior art keywords
patients
formulations
fak
peg
bioactive compounds
Prior art date
Application number
MX2012014982A
Other languages
English (en)
Other versions
MX340819B (es
Inventor
Andrew Xian Chen
Yali J Tsai
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of MX2012014982A publication Critical patent/MX2012014982A/es
Publication of MX340819B publication Critical patent/MX340819B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se dirige a formulaciones de compuestos bioactivos de solubilidad limitada en agua, los inhibidores de quinasa de adhesión focal (FAK) de la clase 2,4-diaminopiridina, adaptados para administración oral a pacientes. Las formulaciones son autoemulsionantes en el tracto gastrointestinal de los pacientes, proporcionando una absorción y biodispoibilidad mejorada de los compuestos bioactivos como dispersiones o emulsiones en una base oleosa. Por ejemplo, los ésteres de glicerol PEG-ilado se pueden utilizar como el aceite, junto con un tensioactivos tales como lecitina y succinato de TEPG y solubilizantes tales como PEG 400 para proporcionar formulaciones orales útiles para administración a pacientes que tengan una mala condición, en donde la inhibición de FAK está indicada medicamente, tal como cáncer o artritis.
MX2012014982A 2010-06-29 2011-06-28 Formulacion oral de inhibidores de quinasa. MX340819B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35969410P 2010-06-29 2010-06-29
PCT/US2011/042162 WO2012006081A1 (en) 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2012014982A true MX2012014982A (es) 2013-07-03
MX340819B MX340819B (es) 2016-07-26

Family

ID=45441513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014982A MX340819B (es) 2010-06-29 2011-06-28 Formulacion oral de inhibidores de quinasa.

Country Status (10)

Country Link
US (1) US9375402B2 (es)
EP (1) EP2588081A4 (es)
JP (1) JP5936609B2 (es)
CN (1) CN103313697B (es)
AU (1) AU2011276552B2 (es)
CA (1) CA2803004A1 (es)
MX (1) MX340819B (es)
NZ (1) NZ604583A (es)
WO (1) WO2012006081A1 (es)
ZA (1) ZA201300009B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
JP5937111B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ Ｆａｋ阻害剤
CA2871820C (en) 2012-05-10 2020-11-03 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE417608T1 (de) 2000-10-11 2009-01-15 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
SG172700A1 (en) 2006-04-28 2011-07-28 Schering Corp Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
DK2046292T3 (da) 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
DK2134689T3 (da) * 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
BRPI0914927B8 (pt) 2008-06-17 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto
WO2011019943A1 (en) 2009-08-12 2011-02-17 Poniard Pharmaceuticals, Inc. Method of promoting apoptosis and inhibiting metastasis
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
ZA201300009B (en) 2013-09-25
US20140206692A1 (en) 2014-07-24
AU2011276552B2 (en) 2015-09-03
WO2012006081A1 (en) 2012-01-12
CN103313697B (zh) 2016-06-01
JP5936609B2 (ja) 2016-06-22
JP2013529686A (ja) 2013-07-22
EP2588081A1 (en) 2013-05-08
US9375402B2 (en) 2016-06-28
CA2803004A1 (en) 2012-01-12
MX340819B (es) 2016-07-26
EP2588081A4 (en) 2014-12-10
AU2011276552A1 (en) 2013-01-10
CN103313697A (zh) 2013-09-18
NZ604583A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
PA8803201A1 (es) Derivados acidos de cicloalquilamino
WO2008016522A3 (en) Hiv reverse transcriptase inhibitors
GT201300159A (es) Composiciones y metodos para modular el fxr
GT201400196A (es) Compuestos de heterociclilo
GEP20125459B (en) Compounds for inhibiting mitotic progression
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
AR073077A1 (es) Uso de dabigatran. compuesto. composicion farmaceutica-
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
WO2012032415A3 (en) Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
WO2008011117A3 (en) Antiviral protease inhibitors
MX2010005714A (es) Compuestos de piridina.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
AR063027A1 (es) Derivados de sulfonamida

Legal Events

Date Code Title Description
FG Grant or registration